The Effect of Fedratinib, a Selective Inhibitor of Janus Kinase 2 (JAK2), on Weight and Metabolic Parameters in Patients with Intermediate (INT)- or High-risk Myelofibrosis (MF)

被引：0
|
作者：
Tremblay, Douglas
Cavalli, Lara
Banerjee, Sibabrata Raja
Rose, Shelonitda
Mascarenhas, John
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-137293
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] LONG-TERM FOLLOW UP OF A PHASE 1/2 STUDY OF SAR302503, AN ORAL JAK2 SELECTIVE INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF)
    Gotlib, J.
    Pardanani, A.
    Jamieson, C.
    Cortes, J.
    Talpaz, M.
    Stone, R.
    Gao, G.
    Zhang, J.
    Neumann, F.
    Lebedinsky, C.
    Tefferi, A.
    HAEMATOLOGICA, 2012, 97 : 145 - 145
  • [22] Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis
    Jamieson, Catriona H. M.
    Hasserjian, Robert P.
    Gotlib, Jason
    Cortes, Jorge E.
    Stone, Richard M.
    Talpaz, Moshe
    Thiele, Juergen
    Rodig, Scott
    Patki, Abhay
    Wu, Kaida
    Wu, Jingyang
    Pozdnyakova, Olga
    BLOOD, 2013, 122 (21)
  • [23] Ruxolitinib, a Janus Kinase (JAK)-1 and-2 Inhibitor Modulates Microrna (miR) Levels in Patients with Myelofibrosis (MF): miR Levels Might Predict MF Treatment Outcome
    Manshouri, Taghi
    Estrov, Zeev
    Knez, Liza
    Zhang, Ying
    Levine, Ross L.
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    BLOOD, 2011, 118 (21) : 761 - 761
  • [24] BMS-986158, a potent bromodomain and extraterminal inhibitor (BETi), as monotherapy and in combination with ruxolitinib or fedratinib, in intermediate- or high-risk myelofibrosis (MF): results from a phase 1/2 study
    Al-Ali, Haifa
    Ayala, Rosa
    Lopez, Nieves
    Abulafia, Adi Shacham
    Alwan, Maan
    Yannakou, Costas K.
    Raman, Indu
    Ribrag, Vincent
    Fong, Chung Yew
    Volchek, Yulia
    Bonifacio, Massimiliano
    Tucci, Alessandra
    Kiladjian, Jean-Jacques
    Hernandez Rivas, Jesus Maria
    Xicoy, Blanca
    Ianotto, Jean-Christophe
    Lee-Hoeflich, Si Tuen
    Das, Sharmilla
    Wu, Bin
    Zhao, Qian
    Esposito, Oriana
    Liu, Yu
    Nikolova, Zariana
    Tehlirian, Christopher
    Coker, Shodeinde
    Lavie, David
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 158 - 159
  • [25] A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
    Pardanani, A.
    Tefferi, A.
    Jamieson, C.
    Gabrail, N. Y.
    Lebedinsky, C.
    Gao, G.
    Liu, F.
    Xu, C.
    Cao, H.
    Talpaz, M.
    BLOOD CANCER JOURNAL, 2015, 5 : e335 - e335
  • [26] A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
    A Pardanani
    A Tefferi
    C Jamieson
    N Y Gabrail
    C Lebedinsky
    G Gao
    F Liu
    C Xu
    H Cao
    M Talpaz
    Blood Cancer Journal, 2015, 5 : e335 - e335
  • [27] Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis
    Pardanani, Animesh
    Tefferi, Ayalew
    Masszi, Tamas
    Mishchenko, Elena
    Drummond, Mark
    Jourdan, Eric
    Vannucchi, Alessandro
    Jurgutis, Mindaugas
    Ribrag, Vincent
    Rambaldi, Alessandro
    Koh, Liang Piu
    Rose, Shelonitda
    Zhang, Jun
    Harrison, Claire
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 195 (02) : 244 - 248
  • [28] Phase I Study Of LY2784544, a JAK2 Selective Inhibitor, In Patients With Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)
    Verstovsek, Srdan
    Mesa, Ruben A.
    Salama, Mohamed E.
    Giles, Jennifer L. K.
    Pitou, Celine
    Zimmermann, Annamaria Hayden
    Price, Gregory L.
    Walgreen, Richard A.
    Prchal, Josef
    BLOOD, 2013, 122 (21)
  • [29] A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study
    Zhou, Yile
    Huang, Jian
    Wen, Bingbing
    Zhou, Hu
    Yang, Wei
    Fan, Lianlian
    Gong, Tiejun
    Gao, Sujun
    Jiao, Zongjiu
    Liu, Qingchi
    Zhao, Lidong
    Wu, Guocai
    Wu, Cuicui
    Wang, Jun
    Zhang, Jin
    Fu, Jiaping
    Sheng, Zengmei
    Zhu, Zunmin
    Lu, Jian
    Zhang, Yi
    Jin, Jie
    BLOOD, 2024, 144 : 1808 - 1809
  • [30] A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF
    Talpaz, Moshe
    Jamieson, Catriona
    Gabrail, Nashat Y.
    Lebedinsky, Claudia
    Gao, Guozhi
    Liu, Feng
    Tefferi, Ayalew
    Pardanani, Animesh
    BLOOD, 2012, 120 (21)
12345